Professor of Medicine
Department of Oncology
Stanford University Medical Center
Stanford Cancer Center
Ranjana Advani, MD, has disclosed that she has received consulting fees from Bayer, Bristol-Myers Squibb, Cell Medica, Genentech/Roche, Gilead Sciences, Juno, NanoString, Pharmacyclics, Spectrum, and Sutro and funds for research support from Agensys, Bristol-Myers Squibb, Celgene, Forty Seven Inc, Genentech/Roche, Janssen, Infinity, Kura, Merck, Millennium, Pharmacyclics, Regeneron, and Seattle Genetics.
Department of Hematology
City of Hope
Robert W. Chen, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Genentech, Merck, and Seattle Genetics and funds for research support from Bristol-Myers Squibb, Pharmacyclics, and Seattle Genetics.
Professor and Chief
Division of Hematology/Oncology
Tufts Medical Center
Andrew M. Evens, DO, MSc, FACP, has disclosed that he has received consulting fees from AbbVie, Affimed, Amgen, Celgene, Kite Pharma, Merck, Millennium, Novartis, Pharmacyclics, Seattle Genetics, and Spectrum; fees for non-CME/CE services from Celgene; and funds for research support from Millennium/Takeda and Seattle Genetics.
Professor of Hematology
Chief of Lymphoma and CLL Unit
Institute of Hematology "Seràgnoli"
University of Bologna
Pier Luigi Zinzani, MD, PhD, has disclosed that he has received consulting fees from Astellas, Bristol-Myers Squibb, Celgene, Gilead Sciences, Janssen, Lundbeck, Merck, Mundipharma, Nordic Nanovector, Roche, Sandoz, Servier, Takeda, and Verastem.
Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
Editorial Director, Hematology/Oncology
Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
Senior Managing Editor
Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.
This program is intended for physicians and other healthcare providers who care for patients with Hodgkin lymphoma.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 24, 2018, through January 23, 2019:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.
In this downloadable slideset, Elizabeth R. Plimack, MD, MS, discusses the current clinical rationale and most recent data on immune checkpoint inhibitors for patients with advanced bladder cancer. Click here to use our online tool to see how to select optimal therapy for your patients.
In this archived Webcast, Raajit K. Rampal, MD, PhD, provides expert perspectives on the diagnosis and optimal management of patients with polycythemia vera or myelofibrosis.
Induction therapy in mantle cell lymphoma is rapidly evolving. How do you treat your patients with MCL?
Download this PDF resource of expert recommendations on the optimal use of immune checkpoint inhibitors in patients with advanced NSCLC, including therapy selection and adverse event management.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.